Targeting DNA repair mechanisms in acute myeloid leukemia
AML mutation-guided drugging of DNA repair
This study is looking at how specific genetic changes in acute myeloid leukemia (AML) affect the cancer's ability to fix its own DNA, so we can find out which patients might do better with special treatments that take advantage of these weaknesses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Temple Univ of the Commonwealth NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10773017 on NIH RePORTER |
What this research studies
This research investigates how certain mutations in acute myeloid leukemia (AML) affect the cancer's ability to repair DNA damage. By analyzing genetic mutations in AML cells, the study aims to identify which patients may benefit from specific treatments that exploit weaknesses in their DNA repair processes. The approach focuses on using drugs that can induce synthetic lethality, particularly in leukemia stem cells that survive standard treatments. This could lead to more effective therapies for patients with AML by targeting the underlying genetic vulnerabilities of their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who have specific genetic mutations affecting DNA repair mechanisms.
Not a fit: Patients with acute myeloid leukemia who do not have the relevant genetic mutations or those with other types of leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for acute myeloid leukemia, potentially improving survival rates and reducing relapse.
How similar studies have performed: Previous research has shown success in using targeted therapies based on genetic mutations in other cancers, suggesting a promising avenue for AML treatment.
Where this research is happening
Philadelphia, United States
- Temple Univ of the Commonwealth — Philadelphia, United States (Active)
Researchers
- Principal investigator: Skorski, Tomasz — Temple Univ of the Commonwealth
- Study coordinator: Skorski, Tomasz
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.